latest update:
[TrialBase DB]

trial summary · NCT06863402

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

Nemtabrutinib and Pembrolizumab in Patients With Richter Transformation: A Phase II Study

Trial record from the TrialBase DB dataset, status RECRUITING, condition Richter Syndrome, sponsored by Roswell Park Cancer Institute. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT06863402phase PHASE2enrollment 32start 2026-11-15

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

This phase II trial tests how well nemtabrutinib in combination with pembrolizumab works in treating patients with Richter transformation, diffuse large B-cell lymphoma subtype (RT-DLBCL). Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cells (a type of white blood cell) in cancers such as Richter transformation at abnormal levels. This may help keep cancer cells from growing and spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving nemtabrutinib in combination with pembrolizumab may kill more cancer cells in patients with RT-DLBCL.

Source record: https://clinicaltrials.gov/study/NCT06863402

Facts

registry idNCT06863402
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE2
study typeINTERVENTIONAL
lead conditionRichter Syndrome
sponsorRoswell Park Cancer Institute
sponsor classOTHER
enrollment32
start date2026-11-15
primary completion2029-06-01
completion2030-06-01
results postednot reported

Conditions

  • Richter Syndrome
  • Diffuse Large B-Cell Lymphoma
  • Chronic Lymphocytic Leukemia

Interventions

  • Biospecimen Collection
  • Bone Marrow Biopsy
  • Computed Tomography
  • Echocardiography
  • Multigated Acquisition Scan
  • Nemtabrutinib
  • Pembrolizumab
  • Positron Emission Tomography
  • Questionnaire Administration

Countries

  • United States

Intervention types: BIOLOGICAL, DRUG, OTHER, PROCEDURE

Work with this record